Does the media favor NVAX or PRLD?

In the previous week, Novavax had 6 more articles in the media than Prelude Therapeutics. MarketBeat recorded 13 mentions for Novavax and 7 mentions for Prelude Therapeutics. Novavax's average media sentiment score of 0.53 beat Prelude Therapeutics' score of 0.39 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ANAB or PRLD?

In the previous week, Prelude Therapeutics had 3 more articles in the media than AnaptysBio. MarketBeat recorded 7 mentions for Prelude Therapeutics and 4 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.54 beat Prelude Therapeutics' score of 0.39 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is PRLD or FBRX more profitable?

Prelude Therapeutics' return on equity of -75.35% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -75.35% -44.39% Forte Biosciences N/A -94.82% -77.68%

Does the media refer more to PRLD or FBRX?

In the previous week, Prelude Therapeutics had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 7 mentions for Prelude Therapeutics and 1 mentions for Forte Biosciences. Prelude Therapeutics' average media sentiment score of 0.39 beat Forte Biosciences' score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Forte Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALVO or PRLD?

In the previous week, Prelude Therapeutics had 5 more articles in the media than Alvotech. MarketBeat recorded 7 mentions for Prelude Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Prelude Therapeutics' score of 0.39 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is PRLD or BCAX more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -75.35% -44.39% Bicara Therapeutics N/A -41.49% -38.59%

Does the media favor PRLD or BCAX?

In the previous week, Prelude Therapeutics had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Prelude Therapeutics and 6 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.04 beat Prelude Therapeutics' score of 0.39 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Bicara Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prelude Therapeutics (PRLD) Competitors

$4.59 -0.08 (-1.71%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.55 -0.04 (-0.96%)

As of 09/11/2026 07:57 PM Eastern

Compare

PRLD vs. NVAX, ANAB, FBRX, ALVO, and BCAX

Should you buy Prelude Therapeutics stock or one of its competitors? Prelude Therapeutics's main competitors and comparable companies include Novavax (NVAX), AnaptysBio (ANAB), Forte Biosciences (FBRX), Alvotech (ALVO), and Bicara Therapeutics (BCAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prelude Therapeutics compare to Novavax?

Novavax (NASDAQ:NVAX) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Novavax presently has a consensus price target of $14.00, indicating a potential upside of 48.62%. Prelude Therapeutics has a consensus price target of $7.67, indicating a potential upside of 67.03%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Novavax has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.38	$440.30M	-$1.52	N/A
Prelude Therapeutics	$12.14M	30.17	-$99.50M	-$0.73	N/A

Novavax has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

53.0% of Novavax shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Novavax had 6 more articles in the media than Prelude Therapeutics. MarketBeat recorded 13 mentions for Novavax and 7 mentions for Prelude Therapeutics. Novavax's average media sentiment score of 0.53 beat Prelude Therapeutics' score of 0.39 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Prelude Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Summary

Novavax beats Prelude Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

AnaptysBio has higher revenue and earnings than Prelude Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	6.80	-$13.23M	-$1.08	N/A
Prelude Therapeutics	$12.14M	30.17	-$99.50M	-$0.73	N/A

In the previous week, Prelude Therapeutics had 3 more articles in the media than AnaptysBio. MarketBeat recorded 7 mentions for Prelude Therapeutics and 4 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.54 beat Prelude Therapeutics' score of 0.39 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Prelude Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Prelude Therapeutics	N/A	-75.35%	-44.39%

AnaptysBio currently has a consensus target price of $79.85, indicating a potential upside of 48.22%. Prelude Therapeutics has a consensus target price of $7.67, indicating a potential upside of 67.03%. Given Prelude Therapeutics' higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

79.7% of Prelude Therapeutics shares are held by institutional investors. 31.5% of AnaptysBio shares are held by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AnaptysBio has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Summary

Prelude Therapeutics beats AnaptysBio on 9 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to Forte Biosciences?

Prelude Therapeutics (NASDAQ:PRLD) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Forte Biosciences has lower revenue, but higher earnings than Prelude Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	30.17	-$99.50M	-$0.73	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

Prelude Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market.

In the previous week, Prelude Therapeutics had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 7 mentions for Prelude Therapeutics and 1 mentions for Forte Biosciences. Prelude Therapeutics' average media sentiment score of 0.39 beat Forte Biosciences' score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Forte Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prelude Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 67.03%. Forte Biosciences has a consensus target price of $71.67, indicating a potential downside of 6.91%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Prelude Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prelude Therapeutics' return on equity of -75.35% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Forte Biosciences	N/A	-94.82%	-77.68%

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Comparatively, 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Prelude Therapeutics beats Forte Biosciences on 12 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Alvotech has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

In the previous week, Prelude Therapeutics had 5 more articles in the media than Alvotech. MarketBeat recorded 7 mentions for Prelude Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Prelude Therapeutics' score of 0.39 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alvotech currently has a consensus target price of $7.50, suggesting a potential upside of 41.78%. Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 67.03%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Prelude Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Prelude Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-36.31%	-11.92%	-11.73%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Alvotech has higher revenue and earnings than Prelude Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	2.71	$27.92M	-$0.61	N/A
Prelude Therapeutics	$12.14M	30.17	-$99.50M	-$0.73	N/A

79.7% of Prelude Therapeutics shares are held by institutional investors. 0.5% of Alvotech shares are held by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Prelude Therapeutics beats Alvotech on 9 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to Bicara Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Prelude Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 67.03%. Bicara Therapeutics has a consensus target price of $32.64, suggesting a potential upside of 43.08%. Given Prelude Therapeutics' higher probable upside, equities analysts plainly believe Prelude Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Prelude Therapeutics has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	30.17	-$99.50M	-$0.73	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

In the previous week, Prelude Therapeutics had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Prelude Therapeutics and 6 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.04 beat Prelude Therapeutics' score of 0.39 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Bicara Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.82, indicating that its stock price is 182% less volatile than the broader market.

79.7% of Prelude Therapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bicara Therapeutics' return on equity of -41.49% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Summary

Prelude Therapeutics beats Bicara Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRLD vs. The Competition

Export

Metric	Prelude Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$366.30M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-6.29	14.18	274.94	25.36
Price / Sales	30.17	1,374.96	685.44	117.05
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	4.21	15.12	10.33	6.20
Net Income	-$99.50M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-15.93%	-4.34%	-3.32%	-2.35%
1 Month Performance	-14.37%	0.54%	-0.53%	-3.23%
1 Year Performance	306.19%	40.74%	23.51%	8.79%

Prelude Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRLD Prelude Therapeutics	2.325 of 5 stars	$4.59 -1.7%	$7.67 +67.0%	+306.2%	$366.30M	$12.14M	N/A	120	News Coverage
NVAX Novavax	2.0816 of 5 stars	$10.06 +7.3%	$14.00 +39.2%	+18.0%	$1.66B	$1.12B	N/A	1,990	Trending News Analyst Upgrade
ANAB AnaptysBio	2.8385 of 5 stars	$55.85 -2.1%	$79.85 +43.0%	+130.2%	$1.65B	$234.60M	N/A	100	Positive News Upcoming Earnings
FBRX Forte Biosciences	0.854 of 5 stars	$76.99 flat	$71.67 -6.9%	N/A	$1.63B	N/A	N/A	5
ALVO Alvotech	3.1207 of 5 stars	$5.20 +0.1%	$7.50 +44.3%	-34.1%	$1.57B	$588.90M	N/A	1,460	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRLD) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Competitors

PRLD vs. NVAX, ANAB, FBRX, ALVO, and BCAX

How does Prelude Therapeutics compare to Novavax?

Summary

How does Prelude Therapeutics compare to AnaptysBio?

Summary

How does Prelude Therapeutics compare to Forte Biosciences?

Summary

How does Prelude Therapeutics compare to Alvotech?

Summary

How does Prelude Therapeutics compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prelude Therapeutics (PRLD) Competitors

PRLD vs. NVAX, ANAB, FBRX, ALVO, and BCAX

How does Prelude Therapeutics compare to Novavax?

Do analysts recommend NVAX or PRLD?

Which has higher earnings and valuation, NVAX or PRLD?

Which has more volatility and risk, NVAX or PRLD?

Do insiders and institutionals have more ownership in NVAX or PRLD?

Does the media favor NVAX or PRLD?

Is NVAX or PRLD more profitable?

Summary

How does Prelude Therapeutics compare to AnaptysBio?

Which has higher valuation & earnings, ANAB or PRLD?

Does the media prefer ANAB or PRLD?

Is ANAB or PRLD more profitable?

Do analysts rate ANAB or PRLD?

Do insiders & institutionals have more ownership in ANAB or PRLD?

Which has more volatility and risk, ANAB or PRLD?

Summary

How does Prelude Therapeutics compare to Forte Biosciences?

Which has higher valuation & earnings, PRLD or FBRX?

Which has more risk & volatility, PRLD or FBRX?

Does the media refer more to PRLD or FBRX?

Do analysts rate PRLD or FBRX?

Is PRLD or FBRX more profitable?

Do insiders and institutionals believe in PRLD or FBRX?

Summary

How does Prelude Therapeutics compare to Alvotech?

Which has more risk and volatility, ALVO or PRLD?

Does the media prefer ALVO or PRLD?

Do analysts prefer ALVO or PRLD?

Is ALVO or PRLD more profitable?

Which has better valuation & earnings, ALVO or PRLD?

Do institutionals and insiders hold more shares of ALVO or PRLD?

Summary

How does Prelude Therapeutics compare to Bicara Therapeutics?

Do analysts rate PRLD or BCAX?

Which has better earnings & valuation, PRLD or BCAX?

Does the media favor PRLD or BCAX?

Which has more risk and volatility, PRLD or BCAX?

Do insiders and institutionals hold more shares of PRLD or BCAX?

Is PRLD or BCAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools